NTRA
VENTE TOTALE: 28 731 titres (~8 419 408,04 $ US)
- Insiders
- Chapman Steven Leonard, Sheena Jonathan, Rabinowitz Matthew
- Total bought
- —
- Total sold
- $8,419,408
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-07
NTRA presents a moderately constructive setup: improving gross margins and rapid scaling support the 75 liquidity score, while Signatera MRD validation and new partnerships provide genuine near-term catalysts.
The first sentence of the analysis written for NTRA on 2026-09-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 64.8% | 60.3% | 45.5% | 44.4% | 49.1% | |
| Ebit Margin | -11.4% | -10.6% | -39.0% | -65.5% | -74.0% | |
| Ebitda Margin | -9.6% | -8.7% | -35.4% | -61.8% | -72.2% | |
| Operating Profit Margin | -13.4% | -13.1% | -41.2% | -66.0% | -74.8% | |
| Pretax Profit Margin | -11.6% | -11.2% | -40.1% | -66.7% | -75.3% | |
| Continuous Operations Profit Margin | -9.0% | -11.2% | -40.2% | -66.8% | -75.4% | |
| Net Profit Margin | -9.0% | -11.2% | -40.2% | -66.8% | -75.4% | |
| Bottom Line Profit Margin | -9.0% | -11.2% | -40.2% | -66.8% | -75.4% | |
| Current Ratio | 3.393 | 3.999 | 4.096 | 3.903 | 4.993 | |
| Quick Ratio | 3.238 | 3.869 | 3.963 | 3.789 | 4.870 | |
| Solvency Ratio | -0.207 | -0.343 | -0.586 | -0.751 | -0.790 | |
| Cash Ratio | 2.439 | 2.748 | 2.090 | 1.501 | 0.385 | |
| Price To Earnings Ratio | -150.717 | -103.464 | -16.571 | -7.212 | -17.925 | |
| Price To Earnings Growth Ratio | 230.597 | 1.738 | 0.516 | -1.044 | -0.215 | |
| Forward Price To Earnings Growth Ratio | 230.597 | 1.738 | 0.516 | -1.044 | -0.215 | |
| Price To Earnings Diluted Ratio | -150.717 | -103.464 | -16.571 | -7.212 | -17.925 | |
| Price To Earnings Diluted Growth Ratio | 230.597 | 1.738 | 0.516 | -1.044 | -0.215 | |
| Price To Book Ratio | 18.291 | 16.515 | 9.412 | 5.601 | 12.945 | |
| Price To Sales Ratio | 13.582 | 11.635 | 6.654 | 4.819 | 13.521 | |
| Price To Free Cash Flow Ratio | 287.055 | 285.132 | -25.173 | -8.249 | -22.477 | |
| Price To Operating Cash Flow Ratio | 145.477 | 145.528 | -29.169 | -9.161 | -25.228 | |
| Debt To Assets Ratio | 0.085 | 0.113 | 0.307 | 0.320 | 0.321 | |
| Debt To Equity Ratio | 0.125 | 0.157 | 0.578 | 0.632 | 0.608 | |
| Debt To Capital Ratio | 0.111 | 0.135 | 0.366 | 0.387 | 0.378 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.270 | 0.285 | 0.300 | |
| Financial Leverage Ratio | 1.465 | 1.389 | 1.884 | 1.976 | 1.893 | |
| Working Capital Turnover Ratio | 2.209 | 1.711 | 1.169 | 0.924 | 0.813 | |
| Operating Cash Flow Ratio | 0.488 | 0.394 | -0.804 | -1.390 | -1.531 | |
| Operating Cash Flow Sales Ratio | 0.093 | 0.080 | -0.228 | -0.526 | -0.536 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.507 | 0.510 | 1.159 | 1.111 | 1.122 | |
| Debt Service Coverage Ratio | -1.903 | -1.634 | -4.122 | -5.665 | -7.748 | |
| Interest Coverage Ratio | -76.164 | -20.804 | -35.310 | -58.058 | -56.373 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.680 | 1.688 | -3.072 | -5.370 | -6.698 | |
| Operating Cash Flow Coverage Ratio | 1.004 | 0.725 | -0.559 | -0.967 | -0.844 | |
| Capital Expenditure Coverage Ratio | 2.028 | 2.042 | -6.300 | -9.047 | -8.171 | |
| Dividend Paid And Capex Coverage Ratio | 2.028 | 2.042 | -6.300 | -9.047 | -8.171 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -138.116 | -128.205 | -18.272 | -7.757 | -19.423 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 64.8% | ▲4.5% | ▲12.0% |
| Ebit Margin | -11.5% | ▼-0.9% | ▲28.6% |
| Ebitda Margin | -9.6% | ▼-0.8% | ▲28.0% |
| Operating Profit Margin | -13.4% | ▼-0.3% | ▲28.3% |
| Pretax Profit Margin | -11.6% | ▼-0.4% | ▲29.4% |
| Continuous Operations Profit Margin | -9.0% | ▲2.2% | ▲31.5% |
| Net Profit Margin | -9.0% | ▲2.2% | ▲31.5% |
| Bottom Line Profit Margin | -9.0% | ▲2.2% | ▲31.5% |
| Current Ratio | 3.393 | ▼-0.606 | ▼-0.684 |
| Quick Ratio | 3.237 | ▼-0.631 | ▼-0.708 |
| Solvency Ratio | -0.207 | ▲0.136 | ▲0.328 |
| Cash Ratio | 2.439 | ▼-0.309 | ▲0.606 |
| Price To Earnings Ratio | -150.717 | ▼-47.253 | ▼-91.539 |
| Price To Earnings Growth Ratio | 230.597 | ▲228.859 | ▲184.279 |
| Forward Price To Earnings Growth Ratio | 230.597 | ▲228.859 | ▲184.279 |
| Price To Earnings Diluted Ratio | -150.717 | ▼-47.253 | ▼-91.539 |
| Price To Earnings Diluted Growth Ratio | 230.597 | ▲228.859 | ▲184.279 |
| Price To Book Ratio | 18.291 | ▲1.775 | ▲5.738 |
| Price To Sales Ratio | 13.582 | ▲1.947 | ▲3.540 |
| Price To Free Cash Flow Ratio | 287.055 | ▲1.922 | ▲183.797 |
| Price To Operating Cash Flow Ratio | 145.477 | ▼-0.050 | ▲99.988 |
| Debt To Assets Ratio | 0.086 | ▼-0.027 | ▼-0.144 |
| Debt To Equity Ratio | 0.125 | ▼-0.031 | ▼-0.295 |
| Debt To Capital Ratio | 0.111 | ▼-0.024 | ▼-0.164 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.171 |
| Financial Leverage Ratio | 1.465 | ▲0.075 | ▼-0.257 |
| Working Capital Turnover Ratio | 2.209 | ▲0.498 | ▲0.844 |
| Operating Cash Flow Ratio | 0.488 | ▲0.094 | ▲1.056 |
| Operating Cash Flow Sales Ratio | 0.093 | ▲0.013 | ▲0.317 |
| Free Cash Flow Operating Cash Flow Ratio | 0.507 | ▼-0.004 | ▼-0.375 |
| Debt Service Coverage Ratio | -1.903 | ▼-0.269 | ▲2.312 |
| Interest Coverage Ratio | -76.164 | ▼-55.360 | ▼-26.822 |
| Short Term Operating Cash Flow Coverage Ratio | 2.680 | ▲0.992 | ▲4.835 |
| Operating Cash Flow Coverage Ratio | 1.004 | ▲0.279 | ▲1.132 |
| Capital Expenditure Coverage Ratio | 2.027 | ▼-0.015 | ▲5.917 |
| Dividend Paid And Capex Coverage Ratio | 2.027 | ▼-0.015 | ▲5.917 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -138.117 | ▼-9.911 | ▼-75.762 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $31.32B | $19.74B | $7.20B | $3.95B | $8.46B | |
| Enterprise value | $30.46B | $18.98B | $7.00B | $3.93B | $8.77B | |
| EV / Sales | 13.21x | 11.19x | 6.47x | 4.79x | 14.02x | |
| EV / Op. cash flow | 141.47x | 139.94x | -28.36x | -9.12x | -26.16x | |
| EV / Free cash flow | 279.16x | 274.18x | -24.47x | -8.21x | -23.31x | |
| EV / EBITDA | -138.12x | -128.21x | -18.27x | -7.76x | -19.42x | |
| Net debt / EBITDA | 3.91x | 5.12x | 0.52x | 0.04x | -0.69x | |
| Current ratio | 3.39x | 4.00x | 4.10x | 3.90x | 4.99x | |
| Income quality | -1.03x | -0.71x | 0.57x | 0.79x | 0.71x | |
| Graham net-net | $4 | $6 | $4 | $4 | $5 | |
| Tax burden | 77.6% | 100.4% | 100.1% | 100.2% | 100.1% | |
| Interest burden | 101.5% | 106.0% | 103.0% | 101.7% | 101.8% | |
| Working capital | $1.06B | $1.03B | $951.3M | $901.3M | $874.2M | |
| Invested capital | $1.92B | $1.28B | $1.12B | $1.07B | $998.7M | |
| Return on assets | -8.3% | -11.5% | -30.2% | -39.3% | -38.1% | |
| Operating ROA | -14.9% | -14.3% | -31.5% | -41.1% | -43.2% | |
| Return on tangible assets | -10.4% | -11.5% | -30.2% | -39.3% | -38.1% | |
| Return on equity | -12.2% | -15.9% | -56.8% | -77.6% | -72.2% | |
| Return on invested capital | -11.1% | -15.8% | -36.4% | -46.2% | -43.6% | |
| Return on capital employed | -15.0% | -16.9% | -39.3% | -49.9% | -46.0% | |
| Earnings yield | -0.7% | -1.0% | -6.0% | -13.9% | -5.6% | |
| Free cash flow yield | 0.3% | 0.4% | -4.0% | -12.1% | -4.4% | |
| Capex / Op. cash flow | 49.3% | 49.0% | -15.9% | -11.1% | -12.2% | |
| Capex / Depreciation | 244.2% | 214.5% | 162.7% | 285.6% | 364.6% | |
| Capex / Sales | 4.6% | 3.9% | 3.6% | 5.8% | 6.6% | |
| SG&A / Sales | 51.0% | 49.6% | 57.1% | 71.8% | 81.7% | |
| R&D / Sales | 27.1% | 23.8% | 29.6% | 38.6% | 42.2% | |
| Stock comp / Sales | 15.4% | 16.2% | 17.7% | 18.6% | 18.4% | |
| Intangibles / Total assets | 20.5% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 47d | 68d | 94d | 109d | 71d | |
| Days payables outstanding | 15d | 19d | 9d | 25d | 31d | |
| Operating cycle | 78d | 92d | 119d | 137d | 102d | |
| Cash conversion cycle | 63d | 73d | 110d | 112d | 71d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+58.6%EV / Sales ▲+18.1%EV / EBITDA ▼-7.7%EV / Op. cash flow ▲+1.538Earnings yield ▲+0.003
Profitability
Return on equity ▲+0.038Return on assets ▲+0.032Return on invested capital ▲+0.047Return on capital employed ▲+0.019Operating ROA ▼-0.005Income quality ▼-0.322Tax burden ▼-0.227
Efficiency
Days sales outstanding ▼-20.643Days payables outstanding ▼-3.990Operating cycle ▼-14.065Cash conversion cycle ▼-10.075Capex / Sales ▲+0.007R&D / Sales ▲+0.032
Balance-sheet strength
Current ratio ▼-0.606Net debt / EBITDA ▼-1.215Working capital ▲+23936000.000Invested capital ▲+640249000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+270.4%EV / Sales ▼-5.8%EV / EBITDA ▼-611.1%EV / Op. cash flow ▲+167.636Earnings yield ▲+0.049
Profitability
Return on equity ▲+0.600Return on assets ▲+0.298Return on invested capital ▲+0.325Return on capital employed ▲+0.310Operating ROA ▲+0.283Income quality ▼-1.745Tax burden ▼-0.225
Efficiency
Days sales outstanding ▼-24.303Days payables outstanding ▼-16.257Operating cycle ▼-24.331Cash conversion cycle ▼-8.074Capex / Sales ▼-0.020R&D / Sales ▼-0.152
Balance-sheet strength
Current ratio ▼-1.600Net debt / EBITDA ▲+4.600Working capital ▲+181529000.000Invested capital ▲+921508000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-09-22 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-08-22 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Josh S. Gottheimer | Sale | $1,001 - $15,000 |
| 2024-11-20 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Daniel Goldman | Sale | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-02 Why Moderna''s Cancer Vaccine Matters to Investors Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient''s unique biology.
- 2026-09-01 New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT scans serve as the standard tool for assessing treatment response in lymphoma, but their performance is limited, with positive predictive value (PPV) reported as low as 50%.
- 2026-08-31 Caisse de depot et placement du Quebec Buys New Shares in Natera, Inc. $NTRA Caisse de depot et placement du Quebec bought a new position in Natera, Inc. (NASDAQ: NTRA) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,517 shares of the medical research company''s stock, valued at approximately $683,000. A number of other institutional
- 2026-08-29 Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run? The billionaire has good reasons to like this genetic testing leader.
- 2026-08-28 Natera & Angiex Partner to Evaluate AGX101 Response With Signatera NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
- 2026-08-28 Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world''s leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera''s SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including.
- 2026-08-27 Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™ AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and.
- 2026-08-27 ADAR1 Capital Management LLC Makes New Investment in Natera, Inc. $NTRA ADAR1 Capital Management LLC bought a new stake in shares of Natera, Inc. (NASDAQ: NTRA) in the undefined quarter, according to its most recent 13F filing with the SEC. The firm bought 2,147 shares of the medical research company''s stock, valued at approximately $583,000. A number of other large investors also recently made
- 2026-08-27 Avala Global LP Makes New $124.87 Million Investment in Natera, Inc. $NTRA Avala Global LP acquired a new stake in Natera, Inc. (NASDAQ: NTRA) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 460,000 shares of the medical research company''s stock, valued at approximately $124,867,000. Natera comprises about 4.6% of Avala Global
- 2026-08-26 Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here''s What His New Positions Reveal Duquesne Family Office has beefed up its healthcare holdings.